Mar 12, 2019 / 06:05PM GMT
Geoffrey Christopher Meacham - Barclays Bank PLC, Research Division - MD & Senior Research Analyst
Afternoon. My name is Geoff Meacham. I'm the senior biopharma analyst here at Barclays. We are thrilled to have CytomX Therapeutics present this afternoon and speaking of -- on behalf of CytomX is Chairman and CEO, Sean McCarthy. Sean?
Sean A. McCarthy - CytomX Therapeutics, Inc. - Chairman, CEO & President
Great. Thank you very much, Geoff, and good afternoon, everybody. Pleasure to be here to present an update on our company.
So as you'll hear over the next 24 minutes or so, what we're doing at CytomX is really rethinking the therapeutic antibody, initially for the treatment of cancer, rethinking and, if you like, reimagining therapeutic antibodies. Over the course of the next few minutes, I will be making certain forward-looking statements. I refer you to our regulatory filings on our website.
So of course, we all know that therapeutic antibodies are a very successful antibody therapeutic class. These are powerful and potent modalities
CytomX Therapeutics Inc at Barclays Global Healthcare Conference Transcript
Mar 12, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers